TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares stood at 0.63 million during the latest session, with the company’s beta value hitting 2.25. At the last check today, the stock’s price was $35.05, to imply a decrease of -2.23% or -$0.8 in intraday trading. The TGTX share’s 52-week high remains $43.32, putting it -23.59% down since that peak but still an impressive 63.11% since price per share fell to its 52-week low of $12.93. The company has a valuation of $5.51B, with an average of 3.23 million shares in intraday trading volume over the past 10 days and average of 2.76 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for TG Therapeutics Inc (TGTX), translating to a mean rating of 1.38. Of 6 analyst(s) looking at the stock, 0 analyst(s) give TGTX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.16.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
After registering a -2.23% downside in the latest session, TG Therapeutics Inc (TGTX) has traded red over the past five days. The 5-day price performance for the stock is -10.90%, and -5.86% over 30 days. With these gigs, the year-to-date price performance is 16.45%. Short interest in TG Therapeutics Inc (NASDAQ:TGTX) saw shorts transact 26.23 million shares and set a 7.84 days time to cover.
The extremes give us $27.5 and $27.5 for target low and target high price respectively. As such, TGTX has been trading 21.54% off suggested target high and 21.54% from its likely low.
TG Therapeutics Inc (TGTX) estimates and forecasts
The rating firms project that company’s revenue will grow 68.25% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 117.07M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 130.24M.Earnings reports from the last fiscal year show that sales brought in 63.47M and 73.47M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 84.44% before jumping 77.29% in the following quarter.
TGTX Dividends
TG Therapeutics Inc has its next earnings report out on 2025-Mar-02. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc insiders hold 9.38% of total outstanding shares, with institutional holders owning 62.73% of the shares at 69.22% float percentage. In total, 62.73% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.69 million shares (or 9.3645% of shares), all amounting to roughly $243.58 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.39 million shares, or about 7.8688% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $202.6 million.
We also have iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the TG Therapeutics Inc (TGTX) shares. Going by data provided on Feb 28, 2025 , iShares Trust-iShares Core S&P Small-Cap ETF holds roughly 8.51 shares. This is just over 5.42% of the total shares, with a market valuation of $295.37 million. Data from the same date shows that the other fund manager holds a little less at 4.33, or 2.76% of the shares, all valued at about 150.46 million.
